MARKETSAnthera Pharmaceuticals (ANTH) Is Weak On High Volume TodayBy TheStreet WireJul 11, 2016 10:05 AM EDT
MARKETSAnthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public OfferingBy Kurumi FukushimaJul 9, 2015 11:08 AM EDT
JIM CRAMER'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a BelieverBy Chris SahlJun 18, 2015 6:00 AM EDT
JIM CRAMERJim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet YellenBy Chris SahlJun 17, 2015 8:43 PM EDT
INVESTINGThe Top-Performing Biotech Stock During a Sizzling First QuarterBy Adam FeuersteinApr 1, 2015 9:30 AM EDT
STOCKSDecember's Essential, Stock-Moving Biotech Events Explained While Eating TurkeyBy Adam FeuersteinNov 26, 2014 6:00 AM EST
STOCKSBiotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech EventsBy Adam FeuersteinJul 14, 2014 9:30 AM EDT
STOCKSTwo Drugs, Designed To Help Patients, Actually Hurt ThemBy Adam FeuersteinNov 19, 2013 10:38 AM EST
STOCKSBiotech Stock Mailbag: Aveo, Anthera, Amarin, MAP PharmaBy Adam FeuersteinNov 20, 2012 10:17 AM EST
